Adverum Biotechnologies
ADVM | NASDAQ
$4.36
$0.00 (0.00%)
At close: Dec 9, 2025, 4:00 PM ET
+0.00%
(1D)Rating
Key Statistics
Market Data
Market Cap $96.26M
1D Range
4.24 4.36
52W Range
1.78 6.07
Valuation (TTM)
PE -0.51
PB -1.73
EV/EBITDA -0.79
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $8.90
Cash Flow
FCF Yield -143.8%
SBC Adj. FCF Yield -151.7%
SBC Impact -5.5%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -117.4% |
-57.9%
Dil EPS 3Y | 5Y -64.8% |
-46.5%
FCF 3Y | 5Y -23.7% |
0.1%
Returns
ROA -133.8%
ROE 255.3%
ROIC -289.5%
Financial Health
Net Cash
$20.25M
Current Ratio 0.65
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various...
Sector Healthcare
Industry Biotechnology
Employees 155
IPO Date Jul 31, 2014
Website www.adverum.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$5.00
Upside
+14.68%
Buy (0)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ADVM